相似文献
1
Therapeutic Targeting of the General RNA Polymerase II Transcription Machinery.
Int J Mol Sci. 2020 May 9;21(9):3354. doi: 10.3390/ijms21093354.
2
Therapeutic targeting of transcriptional cyclin-dependent kinases.
Transcription. 2019 Apr;10(2):118-136. doi: 10.1080/21541264.2018.1539615. Epub 2018 Nov 9.
3
Cyclin-dependent kinases as therapeutic targets in melanoma.
Pigment Cell Melanoma Res. 2014 May;27(3):351-65. doi: 10.1111/pcmr.12211. Epub 2014 Feb 10.
4
Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor.
Br J Pharmacol. 2014 Jan;171(1):55-68. doi: 10.1111/bph.12408.
5
Cdk7: a kinase at the core of transcription and in the crosshairs of cancer drug discovery.
Transcription. 2019 Apr;10(2):47-56. doi: 10.1080/21541264.2018.1553483. Epub 2018 Dec 6.
6
Dissecting the Pol II transcription cycle and derailing cancer with CDK inhibitors.
Nat Chem Biol. 2020 Jul;16(7):716-724. doi: 10.1038/s41589-020-0563-4. Epub 2020 Jun 22.
7
CDK7 inhibitors as anticancer drugs.
Cancer Metastasis Rev. 2020 Sep;39(3):805-823. doi: 10.1007/s10555-020-09885-8.
8
The promise and current status of CDK12/13 inhibition for the treatment of cancer.
Future Med Chem. 2021 Jan;13(2):117-141. doi: 10.4155/fmc-2020-0240. Epub 2020 Dec 9.
9
Cyclin-dependent kinases as new targets for the prevention and treatment of cancer.
Hematol Oncol Clin North Am. 2002 Oct;16(5):1229-53. doi: 10.1016/s0889-8588(02)00049-7.
10
Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy.
Cancer Discov. 2020 Mar;10(3):351-370. doi: 10.1158/2159-8290.CD-19-0528. Epub 2020 Feb 18.
引用本文的文献
1
Probing the extent of importin-α targeting of the TAF8 NLS by eliminating its cationic net-charge.
Protein Sci. 2025 Sep;34(9):e70272. doi: 10.1002/pro.70272.
2
Atypical R-loops in cancer: decoding molecular chaos for therapeutic gain.
J Transl Med. 2025 Aug 14;23(1):912. doi: 10.1186/s12967-025-06929-x.
3
Novel CDK2/CDK9 inhibitor fadraciclib targets cell survival and DNA damage pathways and synergizes with encorafenib in human colorectal cancer cells with BRAF(V600E).
Oncogenesis. 2025 Aug 6;14(1):27. doi: 10.1038/s41389-025-00574-1.
4
Exploring the molecular mechanism of Xiao Ji () in treating bladder cancer using network pharmacology and molecular docking.
Asian Biomed (Res Rev News). 2025 Apr 30;19(2):94-105. doi: 10.2478/abm-2025-0012. eCollection 2025 Apr.
5
Dynamic O-GlcNAcylation and phosphorylation attract and expel proteins from RNA polymerase II to regulate mRNA maturation.
J Biomed Sci. 2025 Apr 4;32(1):39. doi: 10.1186/s12929-025-01135-9.
6
Bioinformatics analysis of electroacupuncture treatment for ischemic stroke: exploring transcriptional regulatory mechanisms mediated by super-enhancers.
Front Neurosci. 2025 Mar 5;19:1522466. doi: 10.3389/fnins.2025.1522466. eCollection 2025.
7
Integration of gene expression and DNA methylation data using MLA-GNN for liver cancer biomarker mining.
Front Genet. 2024 Dec 23;15:1513938. doi: 10.3389/fgene.2024.1513938. eCollection 2024.
8
Efficacy and safety of TACE combined with traditional Chinese medicine versus TACE alone in hepatocellular carcinoma: bayesian network meta-analysis and pharmacological mechanisms study.
Front Pharmacol. 2024 Dec 6;15:1495343. doi: 10.3389/fphar.2024.1495343. eCollection 2024.
9
RNA kinetics influence the response to transcriptional perturbation in leukaemia cell lines.
NAR Cancer. 2024 Oct 3;6(4):zcae039. doi: 10.1093/narcan/zcae039. eCollection 2024 Dec.
10
Human RNA Polymerase II Segregates from Genes and Nascent RNA and Transcribes in the Presence of DNA-Bound dCas9.
Int J Mol Sci. 2024 Aug 1;25(15):8411. doi: 10.3390/ijms25158411.
本文引用的文献
1
Evaluating phase separation in live cells: diagnosis, caveats, and functional consequences.
Genes Dev. 2019 Dec 1;33(23-24):1619-1634. doi: 10.1101/gad.331520.119. Epub 2019 Oct 8.
2
Pol II phosphorylation regulates a switch between transcriptional and splicing condensates.
Nature. 2019 Aug;572(7770):543-548. doi: 10.1038/s41586-019-1464-0. Epub 2019 Aug 7.
3
Kinase inhibitors: the road ahead.
Nat Rev Drug Discov. 2018 May;17(5):353-377. doi: 10.1038/nrd.2018.21. Epub 2018 Mar 16.
4
ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment.
Mol Cancer Ther. 2018 Jun;17(6):1156-1166. doi: 10.1158/1535-7163.MCT-16-0847. Epub 2018 Mar 15.
5
A Mechanistic Overview of Triptolide and Celastrol, Natural Products from Hook F.
Front Pharmacol. 2018 Feb 14;9:104. doi: 10.3389/fphar.2018.00104. eCollection 2018.
6
CDK9 inhibitors in acute myeloid leukemia.
J Exp Clin Cancer Res. 2018 Feb 23;37(1):36. doi: 10.1186/s13046-018-0704-8.
7
Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation.
Nat Chem Biol. 2018 Feb;14(2):163-170. doi: 10.1038/nchembio.2538. Epub 2017 Dec 18.
8
Mediator Kinase Phosphorylation of STAT1 S727 Promotes Growth of Neoplasms With JAK-STAT Activation.
EBioMedicine. 2017 Dec;26:112-125. doi: 10.1016/j.ebiom.2017.11.013. Epub 2017 Nov 21.
9
c-MYC G-quadruplex binding by the RNA polymerase I inhibitor BMH-21 and analogues revealed by a combined NMR and biochemical Approach.
Biochim Biophys Acta Gen Subj. 2018 Mar;1862(3):615-629. doi: 10.1016/j.bbagen.2017.12.002. Epub 2017 Dec 8.
10
The emerging roles of CDK12 in tumorigenesis.
Cell Div. 2017 Oct 27;12:7. doi: 10.1186/s13008-017-0033-x. eCollection 2017.
Zotero 插件
